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Abstract
Background: Many patients experience local recurrence or metastases after receiving potentially curative
treatment, and early detection of these events is important for disease control. Recent technological advances
make it possible to use blood plasma containing circulating cell-free tumour DNA (ctDNA) as a liquid biopsy. In this
case report we show how serial liquid biopsies can be used to monitor the disease course and detect disease
recurrence in a sarcoma patient.
Case presentation: A 55-year-old male presented with a rapidly growing, painful palpable mass in the left groin
region, and a biopsy revealed a high-grade malignant spindle cell sarcoma. No metastases were detected on
radiologic imaging scans. Using targeted resequencing with a custom 900 cancer gene panel, eight somatic
mutations among them KRAS and NF1, were identified in the primary tumour. Targeted resequencing of plasma
cell-free DNA (ctDNA) collected before and after surgery and at disease progression confirmed the presence of six
of eight mutations at all three time points. The ctDNA level, estimated from the somatic allele frequencies of these
six mutations, was high in plasma taken at the time of surgery, at levels similar to the primary tumour. Detection of
low levels of ctDNA three days after surgery indicated persistent microscopic disease. Repeated radiologic imaging
six weeks postoperatively showed widespread metastatic disease in the lungs, skeleton and the pelvic region. At
this time point there was a dramatic increase in the ctDNA level, reflecting the disease progression of the patient.
The patient had an unusually aggressive cancer, and succumbed to the disease 13 weeks after surgery.
Conclusions: This case report demonstrated that targeted resequencing of ctDNA from longitudinal collected
plasma can be used to monitor disease progression in a soft tissue sarcoma patient, including manifestation of
metastatic disease. The ctDNA represented the genomic profile of the tumour, supporting clinical use of liquid
biopsies to identify tumour-specific mutations as well as recurrent disease.
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Background
Cancers arise through a sequential alteration of the gen-
ome, resulting in a heterogeneous tumour that continu-
ously evolves as the disease progress. Material for
diagnostic examination of solid tumours is routinely ob-
tained through fine-needle biopsies. This procedure
gives limited amount of material, and only provides a
single snap-shot of the genetic alterations in a restricted
part of the tumour. After treatment with curative intent,
radiological imaging of patients to monitor local or dis-
tant recurrences is not done on a routine basis, and im-
aging methods also have limited sensitivity to detect
micrometastases.
Recent advances make it possible to use blood plasma
as a liquid biopsy, examining the circulating cell-free
DNA (cfDNA) shed from both normal and tumour cells
into peripheral blood [1–3]. The circulating cell-free
tumour DNA (ctDNA) has been shown to contain the
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various tumour-specific alterations seen in the pri-
mary and metastatic tumours, and may more accur-
ately represent the genetic profile of the whole
tumour mass compared to DNA from a single biopsy
of a heterogeneous lesion [4]. By repeated sampling
of liquid biopsies, somatic mutations identified in
cfDNA can be used as unique non-invasive tumour-
specific biomarkers for monitoring tumour burden
throughout the disease course. Similar procedures are
now in use for screening of foetal genetic aberrations
using the mothers blood, and in several cases aberra-
tions from malignant tumours have been detected
presymtomatic in pregnant women [5].
Several reports have demonstrated that high-
throughput sequencing of cfDNA may be used for prog-
nosis and molecular stratification, early detection of re-
currence and metastasis, monitoring response to
treatment and identification of resistance mechanisms
[6]. Sequencing of cfDNA has been performed for can-
cers like colorectal, ovarian and breast, showing that the
level of tumour-specific mutations reflects the course of
the disease and the treatment response [7–9].
Sarcomas make up a heterogeneous group of malig-
nant tumours of mainly mesenchymal origin. The overall
five-year survival of all soft tissue sarcoma patients is ap-
proximately 70% [10, 11], and about 75% of soft tissue
sarcomas are highly malignant. Soft tissue sarcomas
often recur locally and/or metastasize, and the median
time to local recurrence is around 1-1½ year and to me-
tastasis about 1 year [12, 13], both decreasing long-term
survival. From a molecular genetics perspective, sarco-
mas are genetic diverse and may have numerous somatic
mutations [14]. The use of high-throughput sequencing
of cfDNAs longitudinally collected during disease pro-
gression, making simultaneous screening for multiple
mutations during the disease course possible, has not yet
been reported for sarcomas. However, a recent study de-
scribed exome sequencing of a primary soft tissue sar-
coma tumour and a single plasma sample collected at
time of metastasis, and showed that new mutations had
appeared in ctDNA after progression on chemotherapy
and targeted treatment [15]. Monitoring of disease bur-
den in one osteosarcoma patient has previously been
demonstrated using PCR to detect somatic rearrange-
ments in plasma [16], and allele-specific PCR has been
used to obtain mutation profiles from plasma of GIST
patients [17].
As part of an ongoing prospective study (CircSarc), we
collected primary tumour and plasma samples taken be-
fore and after surgery and at disease progression from a
soft tissue sarcoma patient. Targeted resequencing was
used to identify somatic mutations in the primary
tumour and monitor the level of ctDNA from plasma
samples during the course of the disease.
Case presentation
A 55-year-old male presented with a rapidly growing,
painful palpable mass in the left groin region involving
the femoral nerve and blood vessels. Magnetic resonance
imaging performed 18 days before surgery revealed a
10.5 x 7.6 x 11.0 cm large intramuscular tumour. No
metastases were detected on CT scans of the chest, ab-
domen and pelvic area performed 14 days before sur-
gery. Microscopic evaluation of a biopsy revealed a high-
grade malignant spindle cell sarcoma (Fig. 1). Due to ex-
tensive locoregional growth into the skeleton and in-
tractable pain, a hemipelvectomy was performed. Small
focus with metastatic disease was detected in two lymph
nodes removed during the surgery. Macroscopic examin-
ation showed a well demarcated nodular tumour with
white and fleshy cutting surface with small necrotic
areas and bleeding. Immunohistochemical analysis
showed positive finding for CD99 and AE1/AE3, and
negative staining for S-100, SMA, EMA and CD31.
Cytogenetic analysis showed massive clonal chromo-
somal rearrangements, and PCR and FISH were negative
for fusion genes normally seen in synovial sarcoma. The
differential diagnoses were synovial sarcoma and malig-
nant peripheral nerve sheath tumour. Lymph node me-
tastasis is more commonly seen in synovial sarcoma and
the immunohistochemical finding is also in favour of a
synovial sarcoma, but the genetic findings did not sup-
port that diagnosis. According to the WHO classification
[18], the tumour was classified as an undifferentiated
spindle cell sarcoma.
Targeted resequencing of the tumour and normal
genomic DNA was performed following a SureSelect
protocol (Agilent Technologies, Santa Clara, Califor-
nia, US) and a custom in-solution capture panel, con-
taining exons of 900 cancer-related genes, developed
by the Norwegian Cancer Genomics Consortium
(NCGC, cancergenomics.no) [19]. The methods are
provided in (Additional file 1). The sequencing re-
vealed eight somatic mutations in the primary
tumour. Among these, seven point mutations were
identified in the genes COL2A1 (intronic), NF1
(p.K354R), PTGS2 (intronic), LRP2 (p.Q4132E), KRAS
(p.G12V), PRRC2C (p.R1257G) and GATA6 (p.A29A),
as well as a frameshift deletion in PRG4 (p.R791fs)
(Table 1 and Additional file 2). Copy number analysis
revealed a homozygote deletion of TP53 (Additional
file 3). Targeted resequencing using a smaller Thun-
derBolts Cancer panel (Raindance Technologies, Bil-
lerica, Massachusetts, US) confirmed the identified
KRAS mutation in the primary tumour at an allele
frequency of 66%, similar to the 60% frequency found
using the 900 gene panel (Additional file 2). The add-
itional seven mutated genes were not included within
the ThunderBolts Cancer panel.
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The patient was scheduled for adjuvant chemotherapy,
but repeated radiologic imaging six weeks postopera-
tively showed widespread macroscopic metastatic disease
in the lungs and skeleton, as well as numerous soft tis-
sue metastases in the pelvic region. Targeted resequen-
cing of the plasma samples, using the NCGC 900 cancer
gene panel, confirmed the presence of six of the eight
above mutations in all three plasma samples with allele
frequencies ranging from 2.1-75% (Fig. 2 and Additional
file 2). The mutation levels in plasma before surgery
were comparable to the ones in the primary tumour
with a Pearson’s correlation of 0.93 between frequencies
in tumour and plasma. The mutations in GATA6 and
PRG4, with the lowest allele frequencies in the primary
tumour, were not detected in the plasma samples. The
mean sequencing depth of the six detected mutations in
all three plasma samples was 260x (11-474x), and the
two undetected had a depth of 360x (199-433x). One
new mutation in the splice site of RAD52, a C > T muta-
tion with an allele frequency of 5.5%, was detected in the
cfDNA collected before surgery. This region was se-
quenced at high coverage, but the mutation was not ob-
served in the primary tumour nor in the plasma samples
collected at later time points (Additional file 2).
Targeted resequencing using the ThunderBolts Cancer
panel confirmed the presence of KRAS (p.G12V)) in all
plasma samples (Additional file 2). No other mutations
with >5% allele frequency were detected in more than
one sample.
The level of total cfDNA was monitored during dis-
ease progression. High quantity of cfDNA was detected
one day before surgery (110 ng/ml plasma), and a de-
crease was seen three days after surgery (76 ng/ml
plasma). Six weeks after surgery, the quantity of cfDNA
had increased to more than twice the initial level present
before the surgery (316 ng/ml plasma) (Fig. 2).
The ctDNA level was estimated from the somatic al-
lele frequency of the recurrent mutations in the genes
COL2A1, NF1, PTGS2, LRP2, KRAS and PRRC2C. The
ctDNA level in plasma collected one day before the sur-
gery (Plasma1) was high, and comparable to the level in
primary tumour. Three days after surgery, the ctDNA
level had dropped, but was still detectable in plasma
(Plasma2). In the sample collected six weeks after sur-
gery (Plasma3), there was again an increase in ctDNA
level similar to the levels before surgery (Fig. 2). When
also taking into account the amount of cfDNA released,
the number of mutated genomes per ml of plasma were
Fig. 1 Examination of tumour tissue (a). Macroscopic examination of tumour in femur after hemipelvectomy. b Histological picture of
heamatoxylin and eosin stained slide of patient biopsy material classified as undifferentiated spindle cell sarcoma
Table 1 Overview of somatic mutations in primary tumour. The sequencing libraries were generated using the SureSelectXT
protocol and a 900 cancer-related custom SureSelect in-solution capture gene panel
Gene Position Reference allele Mutated
allele





COL2A1 chr12:48372367 G C NA 96.0 725 Intron variant
NF1 chr17:29527612 A G p.K354R 92.9 438 Missense variant
PTGS2 chr1:186644059 C A NA 64.0 39 Intron variant
LRP2 chr2:170009376 G C p.Q4132E 61.0 443 Missense variant
KRAS chr12:25398284 C A p.G12V 60.4 699 Missense variant
PRRC2C chr1:171510380 A G p.R1257G 29.0 807 Missense variant
GATA6 chr18:19751192 G T p.A29A 18.9 920 Synonymous variant
PRG4 chr1:186277624 CGTACTACACCT C p.R791fs,p.R884fs,p.R832fs,p.R925fs 10.6 810 Frameshift variant &
feature truncation
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three times higher at this time point than before surgery
(Additional file 4). This reflected the disease progression
of the patient and correlated with the tumour burden, as
multiple distant metastases were detected at this time.
The patient’s general condition was considered too poor
for administering chemotherapy, and he succumbed to
the disease 13 weeks after surgery.
Discussions
In this study, we prospectively collected primary tumour
and normal sample material at surgery and several
plasma samples during the disease course of a high-
grade soft tissue sarcoma patient. Targeted resequencing
of the primary tumour and the normal sample identified
eight somatic mutations of which six were also present
in the plasma samples. Among the mutations, KRAS
(p.G12V) and NF1 (p.K354R) were predicted by dbNSFP
[20] to have a deleterious effect on the protein function.
It has been reported that simultaneous inactivation of
TP53 and activation of KRAS induced quick formation
of spindle-cell sarcoma in soft tissues in double trans-
genic mice [21]. The homozygous deletion of TP53
found in the primary tumour strengthens the histology
observed in the primary tumour. The patient in our
study had an unusually aggressive spindle-cell sarcoma,
supporting KRAS not only as biomarker, but as a driving
gene of the disease progression. NF1, a tumour suppres-
sor that functions as a negative regulator of the Ras
pathway, is among the most frequently mutated genes in
several subtypes of sarcomas. Germline and somatic loss
of NF1 in neurofibromatosis patients cause malignant
peripheral nerve sheath tumours [22] and GISTs [23]. In
addition, somatic NF1 mutations, including deletions,
have been reported in a wide variety of paediatric and
adult soft-tissue sarcomas with complex karyotypes [24,
25]. Although no therapeutics that target KRAS or NF1
are available, our study shows that repeated sampling
using liquid biopsies opens new possibilities to identify
and monitor biomarkers that can be used in targeted
therapies.
The synonymous mutation in GATA6 and the frame-
shift deletion in PRG4 could not be detected in the
plasma samples. Although these regions had a high
coverage, these mutations had the lowest allele fre-
quency in the primary tumour and this may thus be a
sensitivity issue. However, it is also possible that the cells
containing these mutations did not release DNA into
circulation. This shows that the ctDNA gives a good rep-
resentation of the genomic profile of the tumour, but
also emphasize the need to use several mutations when
monitoring disease development. A mutation in RAD52,
a gene involved in DNA recombination, was detected in
the plasma collected before surgery, but was not ob-
served in the primary tumour nor in the plasma sample
collected after surgery or at recurrence. One explanation
for this may be tumour heterogeneity where the cells
Fig. 2 Levels of mutations in ctDNA and total cfDNA level in serial samples during disease progression. The allele frequency of mutations in
COL2A1, NF1, PTGS2, LRP2, KRAS and PRRC2C was quantified in primary tumour (squares) at time of surgery (0d) and in serial plasma samples
(circles) collected one day (−1d) before surgery, three days (3d) and six weeks (6w) after surgery using targeted resequencing. The total level of
cfDNA (normal and tumour) was quantified in plasma samples (hexagon) using Qubit fluorometer. Distal metastases were identified after six
weeks (6w), and the patient succumbed to the disease after 13 weeks (13w) with aggressive metastatic disease
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containing this mutation were not present in the part of
the primary tumour that was sequenced and was not
retained during disease progression. Discrepancy of mu-
tation pattern between DNA from primary tumours and
plasma have also previously been reported [26, 27],
showing that liquid biopsies may better capture all mu-
tations present in the primary tumour and/or liver me-
tastasis and can thus be used to overcome the challenges
posed by intra-tumour genetic heterogeneity [4]. We
show that ctDNA from plasma represents an attractive
and easily available source of sarcoma tumour DNA, al-
though it remains to be seen how ctDNA levels vary
across patients and stages.
The allele frequencies of the six mutated genes in the
cfDNA represent the ctDNA level during disease pro-
gression. Three days after surgery, ctDNA was still de-
tectable in the liquid biospy. cfDNA has a rapid
clearance, with reported half-life from 15 min [28] to
13 h for foetal cfDNA in plasma [29]. Although not de-
tectable by CT before surgery, metastatic disease was de-
tected in two lymph nodes removed during the
hemipelvectomy, and a small amount of ctDNA detected
was likely released from additional undiscovered local
metastases that could not be detected by conventional
diagnostic modalities. The patient had a very aggressive
course of the disease, and metastases were detected both
in soft tissue, skeleton and lungs only a few weeks after
surgery. The plasma collected six weeks after surgery
showed an increase in ctDNA relative to the levels be-
fore surgery, reflecting the presence of a tumour and
rapid disease progression.
The cfDNA can originate from both normal and
tumour cells. Based on the high mutated allele frequen-
cies determined in plasma, the initial level of cfDNA is
dominated by DNA from the tumour. Most of the
cfDNA present three days after surgery is believed to
originate from tissue injury and inflammation of normal
cells as a consequence of the extensive surgery, which
would explain the apparently higher normal contribution
to the cfDNA at this time point. After six weeks, there
was a large increase in cfDNA accompanied with an in-
crease of the mutated allele frequencies. Thus, the quan-
tities of cfDNA present in the plasma reflected the
clinical status of the patient due to the fact that most of
the cfDNA released during disease progression was
tumour derived.
Conclusions
This study is the first report of using targeted resequen-
cing of cfDNA from serial plasma samples to monitor
disease progression in a soft tissue sarcoma patient. The
findings show that the level of tumour-specific muta-
tions in liquid biopsies is correlated to disease course in
sarcomas, including clinical manifestation of metastatic
disease. The longitudinally collected ctDNA allow for
near real-time monitoring of the tumour genome during
disease progression, and the ctDNA gives a good repre-
sentation of the genomic profile of the tumour support-
ing the use of ctDNA from plasma as a liquid biopsy.
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